FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Yolles Robert A. 		2. Issuer Name and Ticker or Trading Symbol

Winston Pharmaceuticals, Inc. [ WPHM ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

C/O WINSTON PHARMACEUTICALS, INC., 100 N. FAIRWAY DRIVE, SUITE 134 		3. Date of Earliest Transaction (MM/DD/YYYY)

9/25/2009
(Street)

VERNON HILLS, IL 60061
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Common Stock Options   $1.36   9/25/2009     A      30000         (1) 9/25/2019   Common Stock   30000   $0   30000   (2) (3) D    

Explanation of Responses:
( 1)  Such options vest in five equal annual installments, commencing 09/25/2010.
( 2)  Reported amount excludes: (i) options to purchase 33,096 shares of the Company's common stock, initially exercisable on 09/09/2003 and expiring on 09/09/2012, at an exercise price of $0.33; (ii) options to purchase 16,548 shares of the Company's common stock, initially exercisable on 09/09/2004 and expiring on 09/09/2013, at an exercise price of $0.33; (iii) options to purchase 33,096 shares of the Company's common stock, initially exercisable on 09/09/2005 and expiring on 09/09/2014, at an exercise price of $0.34; (iv) options to purchase 99,287 shares of the Company's common stock, initially exercisable on 02/18/2006 and expiring on 02/18/2015, at an exercise price of $0.34;
( 3)  (v) options to purchase 33,096 shares of the Company's common stock, initially exercisable on 09/09/2006 and expiring on 09/09/2015, at an exercise price of $0.34; (vi) options to purchase 33,096 shares of the Company's common stock, initially exercisable on 09/09/2007 and expiring on 09/09/2016, at an exercise price of $0.34; and (vii) options to purchase 33,096 shares of the Company's common stock, initially exercisable on 09/09/2008 and expiring on 09/09/2017, at an exercise price of $0.34.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Yolles Robert A.
C/O WINSTON PHARMACEUTICALS, INC.
100 N. FAIRWAY DRIVE, SUITE 134
VERNON HILLS, IL 60061 		X



Signatures
/s/ Yolles, Robert A. 10/1/2009
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Winston Pharmaceuticals (CE) (USOTC:WPHM)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024 Winston Pharmaceuticals (CE) 차트를 더 보려면 여기를 클릭.
Winston Pharmaceuticals (CE) (USOTC:WPHM)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024 Winston Pharmaceuticals (CE) 차트를 더 보려면 여기를 클릭.